Clinical Trials on Psoriasis in Brazil

Total 29 results

Federal University of São Paulo

Completed

Evaluation of the Effectiveness of Resistance Training in Patients With Psoriatic Arthritis (PSA)

Psoriatic Arthritis

Brazil
Federal University of São Paulo

Completed

Comparison of the Effectiveness of Functional Training Versus Resistance Exercises in Patients With Psoriatic Arthritis

Psoriatic Arthritis

Brazil
Universidade Federal do Rio de Janeiro

Unknown

99mTc-anti-TNF-alpha Scintigraphy in the Evaluation of Inflammatory Processes Activity

Arthritis | Psoriatic Arthritis

Brazil
Groupe Hospitalier Pitie-Salpetriere

Completed

Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective. (ReFlaP)

Psoriatic Arthritis

United States, Austria, Brazil, Canada, Estonia, France, Germany, Italy, Romania, Russian Federation, Singapore, Spain, Turkey, United Kingdom
Azidus Brasil

Completed

Efficacy Study of the Combination Mometasone + Salicylic Acid in Patients With Psoriasis (Psoriasis)

Psoriasis

Brazil
Azidus Brasil

Completed

Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis (halobetasol)

Psoriasis

Brazil
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

Psoriatic Arthritis (PsA)

United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis (INVIGORATE 2)

Psoriatic Arthritis

United States, India, Greece, Thailand, Czechia, Philippines, Bulgaria, Russian Federation, Guatemala, South Africa, Malaysia, Colombia, Brazil, Poland, Turkey
Novartis Pharmaceuticals

Completed

Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis (FUTURE 1 ext)

Psoriatic Arthritis

United Kingdom, Belgium, Germany, Thailand, Israel, United States, Philippines, Singapore, Italy, Argentina, Russian Federation, Bulgaria, Czechia, Australia, Canada, Poland, Brazil, Slovakia
AbbVie

Completed

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL) (CONTROL)

Psoriatic Arthritis

United States, Australia, Brazil, Bulgaria, Canada, Colombia, Czechia, Germany, Italy, Poland, Puerto Rico, Qatar, Spain, United Kingdom
Bristol-Myers Squibb

Completed

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis (ASTRAEA)

Psoriatic Arthritis

Italy, South Africa, United States, Spain, Germany, Mexico, Israel, France, Greece, Canada, Brazil, Czechia, Peru, Poland, Argentina, Colombia, Chile
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (FUTURE 1)

Psoriatic Arthritis

Germany, United Kingdom, United States, Belgium, Philippines, Singapore, Thailand, Brazil, Czech Republic, Italy, Argentina, Israel, Russian Federation, Bulgaria, Romania, Australia, Canada, Poland, Slovakia
Pfizer

Completed

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors (OPAL BEYOND)

Psoriatic Arthritis

United States, Belgium, Spain, Taiwan, Australia, Brazil, Czechia, France, Germany, Mexico, Poland, Russian Federation, Slovakia, United Kingdom
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, Germany, Greece, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico and more
Hoffmann-La Roche

Completed

A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.

Psoriasis

Brazil
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) (SELECT - PsA 2)

Psoriatic Arthritis

United States, Belgium, Brazil, Canada, Chile, Czechia, France, Greece, Hungary, Italy, Japan, Netherlands, New Zealand, Portugal, Puerto Rico, Spain, United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Psoriatic Arthritis

Russian Federation, United States, Argentina, Australia, Brazil, Bulgaria, Chile, China, Colombia, Czechia, Finland, France, Hungary, Ireland, Italy, Mexico, Poland, Romania, Spain, Taiwan, United Kingdom
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more
UCB BIOSCIENCES GmbH

Completed

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

Arthritis, Psoriatic

Germany, United States, Argentina, Belgium, Brazil, Canada, Czechia, France, Hungary, Ireland, Italy, Mexico, Poland, Spain, United Kingdom
Boehringer Ingelheim

Recruiting

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

Generalized Pustular Psoriasis

Korea, Republic of, Australia, Taiwan, Italy, Spain, Belgium, China, Malaysia, Singapore, United States, Turkey, Germany, France, Tunisia, Brazil, Thailand, India, South Africa
AbbVie

Completed

A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

Brazil
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Australia, Mexico, Canada, United Kingdom, France, Argentina, Japan, Poland, Spain, Korea, Republic of, Brazil, Germany, Romania
Pfizer

Completed

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis (OPAL BALANCE)

Arthritis, Psoriatic

Belgium, United States, Canada, Spain, Australia, Taiwan, Czechia, Hungary, Germany, Mexico, Poland, Russian Federation, Slovakia, United Kingdom, Brazil, Bulgaria
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

Plaque Psoriasis

United States, Korea, Republic of, Taiwan, Germany, Poland, Brazil, Spain, Hungary, Australia, Canada, Romania
Janssen Pharmaceutica

Completed

A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis

Psoriasis | Plaque

Brazil
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Korea, Republic of, United Kingdom, United States, Poland, Germany, Brazil, Spain, Taiwan, Hungary, Japan, Canada, Argentina, Australia
Novartis Pharmaceuticals

Active, not recruiting

A Registry of Patients With Moderate to Severe Plaque Psoriasis (PURE)

Psoriasis

Argentina, Canada, Guatemala, Mexico, Brazil, Costa Rica, Dominican Republic, Panama
Pfizer

Completed

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

United States, Denmark, Slovakia, Canada, Australia, Argentina, Bulgaria, Netherlands, United Kingdom, Brazil, Finland, Greece
Pfizer

Terminated

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

United States, Spain, Korea, Republic of, Taiwan, Canada, Poland, Belgium, Denmark, Germany, Serbia, United Kingdom, France, Czechia, Hungary, Mexico, Colombia, Russian Federation, Croatia, Singapore, Australia, Austria, Slovakia, S... and more

Clinical Trials on Psoriasis in Brazil

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations